ZyVersa Therapeutics (ZVSA) Projected to Post Quarterly Earnings on Wednesday

ZyVersa Therapeutics (NASDAQ:ZVSA) will likely be announcing its Q4 2025 resultson Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, April 2, 2026 at 9:30 AM ET.

ZyVersa Therapeutics Stock Down 0.9%

NASDAQ ZVSA opened at $0.22 on Wednesday. The stock has a market capitalization of $1.75 million, a PE ratio of -0.16 and a beta of 0.66. ZyVersa Therapeutics has a 12-month low of $0.11 and a 12-month high of $1.94. The company has a 50 day moving average price of $0.22 and a two-hundred day moving average price of $0.17.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.